Infect Chemother.  2010 Feb;42(1):6-11. 10.3947/ic.2010.42.1.6.

General Features and Post-Exposure Prophylaxis of Rabies

Affiliations
  • 1Division of Arboviruses, National Institute of Health, Korea Centers for Disease Control and Prevention, Seoul, Korea. mghan@korea.kr

Abstract

Rabies is a representative zoonotic disease caused by rabies virus. The discriminative features of rabies are broad range of hosts including humans, a wide variety of incubation periods ranging from a few weeks to more than a year, ability to bring about acute fetal consequence, and scare pathological lesions. Although rabies is fatal, it is preventable disease by vaccination and post-exposure prophylaxis (PEP). This review will focus on general features of rabies, and immunoglobulin and vaccines for PEP.

Keyword

Rabies; vaccine; post-exposure prophylaxis

MeSH Terms

Humans
Immunoglobulins
Oligopeptides
Post-Exposure Prophylaxis
Rabies
Rabies virus
Vaccination
Vaccines
Immunoglobulins
Oligopeptides
Vaccines

Figure

  • Figure 1 High- and suspect-risk regions of rabies. High-risk and suspect-risk regions are indicated in blue and light blue, respectively. The areas where rabies in humans and animals was reported since 1993 were designated as high-risk region of rabies.

  • Figure 2 Guideline on post-exposure prophylaxis for animal bite patients (Korea CDC, 2007).

  • Figure 3 Management of animals to determine post-exposure treatment in 2008. (A) Bite cases by animals vaccinated to rabies. (B) Bite cases by unvaccinated animals.


Cited by  2 articles

Prophylaxis of Human Hydrophobia in South Korea
Yang Ree Kim
Infect Chemother. 2014;46(3):143-148.    doi: 10.3947/ic.2014.46.3.143.

Five Year Experience of Preexposure and Postexposure Rabies Prophylaxis in Korean Children at the National Medical Center
Jin Chul Noh, Hyang Mi Park, Jong Hyun Park, Youn Kyung Won, Chang Hyu Lee, Jae Yoon Kim
Korean J Pediatr Infect Dis. 2013;20(1):9-16.    doi: 10.14776/kjpid.2013.20.1.9.


Reference

1. Rupprecht CE, Hanlon CA, Hemachudha T. Rabies re-examined. Lancet Infect Dis. 2002. 2:327–343.
Article
2. Smith JS, Fishbein DB, Rupprecht CE, Clark K. Unexplained rabies in three immigrants in the United States. A virologic investigation. N Engl J Med. 1991. 324:205–211.
Article
3. Grattan-Smith PJ, O'Regan WJ, Ellis PS, O'Flaherty SJ, McIntyre PB, Barnes CJ. Rabies. A second Australian case, with a long incubation period. Med J Aust. 1992. 156:651–654.
Article
4. Johnson N, Fooks A, McColl K. Human rabies case with long incubation, Australia. Emerg Infect Dis. 2008. 14:1950–1951.
5. Jackson AC, Warrell MJ, Rupprecht CE, Ertl HC, Dietzschold B, O'Reilly M, Leach RP, Fu ZF, Wunner WH, Bleck TP, Wilde H. Management of rabies in humans. Clin Infect Dis. 2003. 36:60–63.
Article
6. Wilde H, Hemachudha T, Jackson AC. Viewpoint: Management of human rabies. Trans R Soc Trop Med. Hyg. 2008. 102:979–982.
7. Hattwick MA, Weis TT, Stechschulte CJ, Baer GM, Gregg MB. Recovery from rabies. A case report. Ann Intern Med. 1972. 76:931–942.
8. Hattwick MAW. Human rabies. Public Health Rev. 1974. 3:229–274.
9. Willoughby RE Jr, Tieves KS, Hoffman GM, Ghanayem NS, Amlie-Lefond CM, Schwabe MJ, Chusid MJ, Rupprecht CE. Survival after treatment of rabies with induction of coma. N Engl J Med. 2005. 352:2508–2514.
Article
10. Warrell MJ, Warrell DA. Rabies and other lyssavirus diseases. Lancet. 2004. 363:959–969.
Article
11. Noah DL, Drenzek CL, Smith JS, Krebs JW, Orciari L, Shaddock J, Sanderlin D, Whitfield S, Fekadu M, Olson JG, Rupprecht CE, Childs JE. Epidemiology of human rabies in the United States, 1980 to 1996. Ann Intern Med. 1998. 128:922–930.
Article
12. Kim CH, Lee CG, Yoon HC, Nam HM, Park CK, Lee JC, Kang MI, Wee SH. Rabies, an emerging disease in Korea. J Vet Med B Infect Dis Vet Public Health. 2006. 53:111–115.
Article
13. Korea Centers for Disease Control and Prevention. Human Rabies Prevention & Control. 2007.
14. Han MY, Cho JE, Seo SY, Jeong YE. Epidemiological features of animal bite cases occurred in highly risk areas of rabies in Korea, 2005 to 2008. 2009. In : 20th International Conference on Rabies in the Americas; 45–46.
15. Rabies facts. Alliance for Rabies Control. Accessed 10 February 2009. Available at: http://www.rabiescontrol.net/EN/About-Rabies/Rabies-Facts.html.
16. Knobel DL, Cleaveland S, Coleman PG, Fèvre EM, Meltzer MI, Miranda ME, Shaw A, Zinsstag J, Meslin FX. Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ. 2005. 83:360–368.
17. WHO. WHO Expert Consultation on rabies. World Health Organ Tech Rep Ser. 2005. 931:1–88.
18. Bronnert J, Wilde H, Tepsumethanon V, Lumlertdacha B, Hemachudha T. Organ transplantations and rabies transmission. J Travel Med. 2007. 14:177–180.
19. Conomy JP, Leibovitz A, McCombs W, Stinson J. Airborne rabies encephalitis: demonstration of rabies virus in the human central nervous system. Neurology. 1977. 27:67–69.
Article
20. Gibbons RV. Cryptogenic rabies, bats, and the question of aerosol transmission. Ann Emerg Med. 2002. 39:528–536.
Article
21. Johnson N, Brookes SM, Fooks AR, Ross RS. Review of human rabies cases in the UK and in Germany. Vet Rec. 2005. 157:715.
Article
22. Srinivasan A, Burton EC, Kuehnert MJ, Rupprecht C, Sutker WL, Ksiazek TG, Paddock CD, Guarner J, Shieh WJ, Goldsmith C, Hanlon CA, Zoretic J, Fischbach B, Niezgoda M, El-Feky WH, Orciari L, Sanchez EQ, Likos A, Klintmalm GB, Cardo D, LeDuc J, Chamberland ME, Jernigan DB, Zaki SR. Rabies in Transplant Recipients Investigation Team. Transmission of rabies virus from an organ donor to four transplant recipients. N Engl J Med. 2005. 352:1103–1111.
Article
23. Pará M. An outbreak of post-vaccinal rabies (rage de laboratoire) in Fortaleza, Brazil, in 1960. Residual fixed virus as the etiological agent. Bull World Health Organ. 1965. 33:177–182.
24. Jackson AC. Rabies. Neurol Clin. 2008. 26:717–726.
Article
25. Iwasaki Y, Tobita M. Jackson AC, Wunner WH, editors. Pathology. Rabies. 2002. San Diego: Academic Press;283–306.
Article
26. Fu ZF, Jackson AC. Neuronal dysfunction and death in rabies virus infection. J Neurovirol. 2005. 11:101–106.
Article
27. Dacheux L, Reynes JM, Buchy P, Sivuth O, Diop BM, Rousset D, Rathat C, Jolly N, Dufourcq JB, Nareth C, Diop S, Iehlé C, Rajerison R, Sadorge C, Bourhy H. A reliable diagnosis of human rabies based on analysis of skin biopsy specimens. Clin Infect Dis. 2008. 47:1410–1417.
Article
28. Woldehiwet Z. Clinical laboratory advances in the detection of rabies virus. Clin Chim Acta. 2005. 351:49–63.
Article
29. Crepin P, Audry L, Rotivel Y, Gacoin A, Caroff C, Bourhy H. Intravitam diagnosis of human rabies by PCR using saliva and cerebrospinal fluid. J Clin Microbiol. 1998. 36:1117–1121.
Article
30. Hemachudha T, Griffin DE, Giffels JJ, Johnson RT, Moser AB, Phanuphak P. Myelin basic protein as an encephalitogen in encephalomyelitis and polyneuritis following rabies vaccination. N Engl J Med. 1987. 316:369–374.
Article
31. Piyasirisilp S, Hemachudha T. Neurological adverse events associated with vaccination. Curr Opin Neurol. 2002. 15:333–338.
Article
32. Swamy HS, Anisya V, Nandi SS, Kaliaperumal VG. Neurological complications due to Semple-type antirabies vaccine. Clinical and therapeutic aspects. J Assoc Physicians India. 1991. 39:667–669.
33. WHO recommendations on rabies post-exposure treatment and the correct technique of intradermal immunization against rabies. WHO. Accessed 19 February 2010. Available at: http://www.who.int/rabies/en/WHO_recommendation_post_exp_treatment.pdf.
34. Rupprecht CE, Briggs D, Brown CM, Franka R, Katz SL, Kerr HD, Lett S, Levis R, Meltzer MI, Schaffner W, Cieslak PR. Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals. Vaccine. 2009. 27:7141–7148.
Article
35. Aoki FY, Rubin ME, Friesen AD, Bowman JM, Saunders JR. Intravenous human rabies immunoglobulin for post-exposure prophylaxis: serum rabies neutralizing antibody concentrations and side-effects. J Biol Stand. 1989. 17:91–104.
Article
36. Champion JM, Kean RB, Rupprecht CE, Notkins AL, Koprowski H, Dietzschold B, Hooper DC. The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure. J Immunol Methods. 2000. 235:81–90.
Article
37. Bakker AB, Python C, Kissling CJ, Pandya P, Marissen WE, Brink MF, Lagerwerf F, Worst S, van Corven E, Kostense S, Hartmann K, Weverling GJ, Uytdehaag F, Herzog C, Briggs DJ, Rupprecht CE, Grimaldi R, Goudsmit J. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine. 2008. 26:5922–5927.
Article
38. Goudsmit J, Marissen WE, Weldon WC, Niezgoda M, Hanlon CA, Rice AB, Kruif J, Dietzschold B, Bakker AB, Rupprecht CE. Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin. J Infect Dis. 2006. 193:796–801.
Article
39. Rabies vaccines. WHO position paper. Wkly Epidemiol Rec. 2007. 82:425–435.
Full Text Links
  • IC
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr